Kim Steegen

Publications

43

Citations

1.1K

h-index

19

Publishing journals

27

Years of publications

19

Active since

2007

References

1.3K

Institutions

7

1. Virological Findings and Treatment Outcomes of Cases That Developed Dolutegravir Resistance in Malawi’s National HIV Treatment Program
   Viruses, Volume 16, Issue 1, No. 29, Page 29, Year 2024
2. K103N, V106M and Y188L Significantly Reduce HIV-1 Subtype C Phenotypic Susceptibility to Doravirine
   Viruses, Volume 16, Issue 9, No. 1493, Page 1493, Year 2024
3. Thymidine Analogue Mutations with M184V Significantly Decrease Phenotypic Susceptibility of HIV-1 Subtype C Reverse Transcriptase to Islatravir
   Viruses, Volume 16, Issue 12, No. 1888, Page 1888, Year 2024
4. Rapid Evaluation of the Xpert® Xpress CoV-2 plus and Xpert® Xpress CoV-2/Flu/RSV plus Tests
   Diagnostics, Volume 13, Issue 1, No. 34, Pages 34-34, Year 2023
5. Impact of rilpivirine cross-resistance on long-acting cabotegravir-rilpivirine in low and middle-income countries
   AIDS (London), Volume 37, Issue 6, Pages 1009-1011, Year 2023
6. Advancing HIV Drug Resistance Technologies and Strategies: Insights from South Africa’s Experience and Future Directions for Resource-Limited Settings
   Diagnostics, Volume 13, Issue 13, No. 2209, Pages 2209-2209, Year 2023
7. Recommendations on data sharing in HIV drug resistance research
   PLoS Medicine, Volume 20, Issue 9 September, No. e1004293, Page e1004293, Year 2023
8. Performance Evaluation of Four Qualitative RT-PCR Assays for the Detection of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
   Microbiology Spectrum, Volume 11, Issue 2, Pages e0371622-e0371622, Year 2023
9. Resistance is common in paediatric patients failing ART in South Africa
   Journal of Antimicrobial Chemotherapy, Volume 78, Issue 5, Pages 1160-1167, Year 2023
10. Dolutegravir Resistance in Malawi’s National HIV Treatment Program
    Open Forum Infectious Diseases, Volume 9, Issue 5, No. ofac148, Pages ofac148-ofac148, Year 2022
11. Long-term HIV treatment outcomes and associated factors in sub-Saharan Africa: multi-country longitudinal cohort analysis
    AIDS (London), Volume 36, Issue 10, Pages 1437-1447, Year 2022
12. Low-level viraemia despite emergence of dolutegravir-resistant variants
    Southern African Journal of HIV Medicine, Volume 23, Issue 1, No. a1398, Year 2022
13. Compelling evidence for unconditional shift to dolutegravir
    The Lancet HIV, Volume 9, Issue 8, Pages e523-e524, Year 2022
14. Guidance for SARS-CoV-2 RNA-Based Molecular Assay Analytical Performance Evaluations
    Methods in Molecular Biology, Volume 2511, Pages 99-115, Year 2022
15. Minimal Cross-resistance to Tenofovir in Children and Adolescents Failing ART Makes Them Eligible for Tenofovir-Lamivudine-Dolutegravir Treatment
    The Pediatric Infectious Disease Journal, Volume 41, Issue 10, Pages 827-834, Year 2022
16. Feasibility and clinical relevance of HIV-1 drug resistance testing in patients with low-level viraemia in South Africa
    Journal of Antimicrobial Chemotherapy, Volume 76, Issue 10, Pages 2659-2665, Year 2021
17. Is there a role for doravirine in African HIV treatment programmes? A large observational resistance study in South Africa
    Journal of the International AIDS Society, Volume 24, Issue 5, No. e25706, Pages e25706-e25706, Year 2021
18. Preparing for the next pandemic: Lessons from rapid scale-up of SARS-CoV-2 testing in a South African high-throughput automated HIV molecular laboratory
    International Journal of Infectious Diseases, Volume 110, Pages 1-3, Year 2021
19. High levels of HIV drug resistance among adults failing second-line antiretroviral therapy in Namibia
    Medicine (United States), Volume 99, Issue 37, Pages e21661-e21661, Year 2020
20. Drug level testing as a strategy to determine eligibility for drug resistance testing after failure of ART: a retrospective analysis of South African adult patients on second‐line ART
    Journal of the International AIDS Society, Volume 23, Issue 6, No. e25501, Pages e25501-e25501, Year 2020

No publications in the index yet.